Did SCYNEXIS (SCYX) report any disagreements related to Gilman’s resignation?

SCYNEXIS specifically stated that Dr. Gilman’s resignation was not the result of any disagreement regarding the company’s operations, policies, practices, strategy, management, or Board. This language is intended to reassure investors that no governance conflict was disclosed.

SCYNEXIS director Gilman to retire at 2026 meeting

SCYNEXIS, Inc. reported that board member Steven C. Gilman plans to retire from the Board and will not stand for reelection at the company’s 2026 annual meeting of stockholders.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

SCYNEXIS, Inc. reported that board member Steven C. Gilman plans to retire from the Board and will not stand for reelection at the company’s 2026 annual meeting of stockholders. His term will end at that meeting, when his current directorship expires.

Until the 2026 annual meeting, Dr. Gilman will continue to serve as Chair of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee. The company stated that his decision was not due to any disagreement regarding its operations, policies, practices, strategy, management, or Board.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Notice date: April 16, 2026 End of term: 2026 annual meeting Common stock par value: $0.001 per share

3 metrics

Notice date April 16, 2026 Date Dr. Gilman notified SCYNEXIS of his intent to retire

End of term 2026 annual meeting When Dr. Gilman’s Board term and service will conclude

Common stock par value $0.001 per share Par value of SCYNEXIS common stock listed on Nasdaq Capital Market

Key Terms

Emerging growth company, Compensation Committee, Nominating and Corporate Governance Committee, annual meeting of stockholders

4 terms

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Compensation Committee financial

"Chair of the Compensation Committee and a member"

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

Nominating and Corporate Governance Committee regulatory

"and a member of the Nominating and Corporate Governance Committee"

A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.

annual meeting of stockholders regulatory

"not stand for reelection at the Company’s 2026 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What director change did SCYNEXIS (SCYX) disclose in this 8-K?

SCYNEXIS disclosed that director Steven C. Gilman intends to retire and will not stand for reelection at the 2026 annual meeting. His current term will therefore end at that meeting, and he will step down from the Board at that time.

When will Steven C. Gilman leave the SCYNEXIS (SCYX) Board?

Steven C. Gilman will leave the SCYNEXIS Board at the company’s 2026 annual meeting of stockholders, when his current term expires. Until then, he remains an active director and continues in his committee leadership and membership roles.

Why is SCYNEXIS director Steven C. Gilman retiring from the Board?

The filing states that Steven C. Gilman notified SCYNEXIS of his intent to retire as a Board member and not stand for reelection at the 2026 annual meeting. His decision is described as a retirement, not tied to any disclosed dispute or controversy.

What Board roles will Steven C. Gilman hold at SCYNEXIS until the 2026 meeting?

Until the 2026 annual meeting, Dr. Gilman will remain Chair of the Compensation Committee and a member of the Nominating and Corporate Governance Committee. He continues to participate in oversight of executive pay and Board governance during this transition period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/20/2026 - 04:01 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): April 16, 2026

    

SCYNEXIS, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-36365	56-2181648
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1 Evertrust Plaza 13th Floor
Jersey City, New Jersey		07302-6548
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 201 884-5485

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	SCYX	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On April 16, 2026, Steven C. Gilman, a member of the Board of Directors (the “Board”) of SCYNEXIS, Inc. (the “Company”), notified the Company of his intent to retire as a member of the Board and therefore not stand for reelection at the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”). Accordingly, Dr. Gilman’s term as a director will end when his current term expires at the 2026 Annual Meeting. Dr. Gilman will remain in his roles as the Chair of the Compensation Committee and a member of the Nominating and Corporate Governance Committee of the Board until the conclusion of the 2026 Annual Meeting. The Company’s management and the Board thank Dr. Gilman for his years of service and valuable contributions to the Company.

Dr. Gilman’s resignation was not the result of any disagreement with the Company on any matter related to the Company’s operations, policies, practices or strategy, the Company’s management or the Board.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			SCYNEXIS, Inc.

Date:	April 20, 2026	By:	/s/ David Angulo, M.D.
		Name:	David Angulo, M.D.
		Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document